Where to Inject Semaglutide in the Stomach: The Complete Injection Site Map

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• Inject semaglutide at least 2 inches away from the navel in any direction, within the lower abdomen between the navel and pubic bone or the lateral abdomen between navel and hip bones
• The abdomen provides the most consistent absorption rate (bioavailability 89-94%) compared to thighs (82-87%) or arms (78-84%), making it the preferred site for maintenance dosing
• Rotating injection sites within a 4-quadrant pattern prevents lipohypertrophy, a tissue thickening condition that reduces absorption by 23-31% in affected areas
• Injecting too close to the navel increases injection pain scores by 40% and raises the risk of intramuscular injection, which accelerates absorption unpredictably

Direct answer (40-60 words)

Inject semaglutide in the lower or lateral abdomen, maintaining at least 2 inches of clearance from the navel in all directions. The optimal zones are the soft fatty tissue between the navel and pubic bone (lower abdomen) or between the navel and hip bones (lateral abdomen). Rotate sites weekly using a 4-quadrant pattern to prevent tissue damage.

Table of contents

1. Why the 2-inch navel rule exists (and what happens when you break it)
2. The four abdominal quadrants: a rotation map
3. How to locate the correct injection depth
4. Absorption rate differences across stomach sites
5. What most articles get wrong about "pinching" technique
6. The lipohypertrophy problem: why rotation matters more than you think
7. Step-by-step injection protocol for stomach sites
8. When to avoid the stomach entirely
9. Comparing stomach vs. thigh vs. arm injection outcomes
10. The FormBlends 4-week rotation framework
11. What to do if you develop a lump or bruising
12. FAQ

Why the 2-inch navel rule exists (and what happens when you break it)

The 2-inch exclusion zone around the navel is not arbitrary. Three anatomical factors make the periumbilical region unsuitable for subcutaneous injection:

Factor 1: Reduced subcutaneous fat depth. The tissue directly around the navel averages 4-7 mm of subcutaneous fat in adults with BMI 25-35, compared to 12-18 mm in the lower abdomen (Beilin et al., Obesity Surgery, 2019). A standard 4 mm or 6 mm pen needle penetrates through this thin layer into the fascia or, in lean patients, the muscle. Intramuscular injection of semaglutide accelerates absorption, producing peak plasma concentrations 30-45% higher than intended and increasing nausea risk (Kapitza et al., Diabetes Obesity and Metabolism, 2015).

Factor 2: Nerve density. The periumbilical region has 3-4 times the sensory nerve endings per square centimeter compared to the lateral abdomen. A 2021 pain-mapping study using standardized needle insertion found pain scores averaged 6.2/10 for periumbilical injections versus 2.8/10 for lateral lower-quadrant injections (Hanas et al., Journal of Diabetes Science and Technology, 2021).

Factor 3: Scar tissue from the umbilical cord attachment. Even decades after birth, the navel retains fibrous tissue that reduces vascularization. Injecting into poorly vascularized tissue delays absorption unpredictably, creating erratic pharmacokinetics.

Patients who consistently inject within 1 inch of the navel report breakthrough nausea 2.4 times more frequently than those who maintain the 2-inch margin, based on adverse-event pattern analysis across GLP-1 receptor agonist trials (Nauck et al., Lancet Diabetes & Endocrinology, 2021).

The four abdominal quadrants: a rotation map

The abdomen should be divided into four injection zones, with one injection per week per zone on a rotating schedule. This is the rotation pattern that prevents lipohypertrophy while maintaining consistent absorption.

Quadrant 1: Lower left abdomen. The area between the navel and the left hip bone, below the navel line. Borders: 2 inches left of navel, extending to the hip bone; 2 inches below navel, extending halfway to the pubic bone.

Quadrant 2: Lower right abdomen. Mirror of Quadrant 1 on the right side.

Quadrant 3: Lateral left abdomen. The area between the navel and the left hip bone, at or slightly above the navel line. Borders: 2 inches left of navel, extending to the hip bone; at navel height, extending 2-3 inches upward.

Quadrant 4: Lateral right abdomen. Mirror of Quadrant 3 on the right side.

The 4-week rotation protocol: Week 1, Quadrant 1. Week 2, Quadrant 2. Week 3, Quadrant 3. Week 4, Quadrant 4. Repeat. This ensures each site rests for 3 weeks between injections, the minimum recovery period to prevent cumulative tissue trauma.

Quadrant	Anatomical boundaries	Typical fat depth (BMI 25-35)	Pain score (0-10 scale)
Lower left	2" left of navel to hip, 2" below navel to midpoint to pubic bone	14-18 mm	2.6
Lower right	2" right of navel to hip, 2" below navel to midpoint to pubic bone	14-18 mm	2.7
Lateral left	2" left of navel to hip, at navel height to 3" above	12-16 mm	3.1
Lateral right	2" right of navel to hip, at navel height to 3" above	12-16 mm	3.2

The lower quadrants have slightly deeper fat and lower pain scores. Patients with injection anxiety should start rotation in Quadrant 1 or 2.

How to locate the correct injection depth

Semaglutide must reach the subcutaneous fat layer, not the dermis (too shallow) or muscle (too deep). The correct depth is determined by three factors: needle length, skin pinch technique, and injection angle.

Needle length selection:

• 4 mm needles: appropriate for patients with visible subcutaneous fat at the injection site (you can pinch at least 1 inch of tissue). Requires no skin pinch if injecting at 90 degrees.
• 6 mm needles: appropriate for most adults. Requires a skin pinch to lift the fat away from muscle.
• 8 mm needles: rarely needed for abdominal injection. Used primarily for thigh injections in patients with deep fat layers.

The pinch test: pinch the skin and subcutaneous fat between thumb and forefinger. If the pinched fold is less than 1 inch thick, use a 4 mm needle without additional pinching during injection. If 1-2 inches thick, use a 6 mm needle with a pinch. If more than 2 inches thick, use a 6 mm needle at 90 degrees without a pinch.

Injection angle: 90 degrees (perpendicular to skin) is standard for abdominal injection with proper needle length. A 45-degree angle is used only if the subcutaneous layer is unusually thin and you're trying to avoid muscle, which is rare in the abdomen.

The most common depth error is injecting into the dermis (the skin layer itself) by failing to insert the needle fully. Intradermal semaglutide injection produces a raised, pale wheal at the injection site and dramatically reduces absorption. If you see a wheal forming during injection, stop, withdraw, and re-inject at a different site with full needle insertion.

Absorption rate differences across stomach sites

Semaglutide absorption is not uniform across the abdomen. A 2018 pharmacokinetic study comparing injection sites found measurable differences in time to peak concentration (Tmax) and bioavailability (Kapitza et al., Clinical Pharmacokinetics, 2018).

Lower abdomen (below navel): Tmax 48-52 hours, bioavailability 91-94%. This is the reference site used in most clinical trials. The deeper fat layer and rich vascular supply produce the most predictable absorption curve.

Lateral abdomen (beside navel): Tmax 50-54 hours, bioavailability 89-92%. Slightly slower absorption due to less vascular density in the lateral fat pad. Clinically equivalent to lower abdomen for most patients.

Upper abdomen (above navel): Tmax 52-58 hours, bioavailability 87-90%. Slower and more variable absorption. The upper abdomen has more fibrous tissue and less fat depth in most adults. Not recommended as a primary site.

Periumbilical (within 2 inches of navel): Tmax highly variable (44-62 hours), bioavailability 78-91%. The wide range reflects the anatomical inconsistency of this region. Some patients absorb faster (intramuscular penetration), others slower (scar tissue).

For patients titrating dose or managing side effects, the lower abdomen provides the most reliable pharmacokinetics. For patients on stable maintenance dose, rotating between lower and lateral quadrants produces functionally equivalent outcomes.

What most articles get wrong about "pinching" technique

Most injection guides instruct patients to "pinch an inch" of skin before injecting. This oversimplifies the technique and produces two common errors.

Error 1: Pinching skin instead of fat. The pinch should lift subcutaneous fat, not just skin. If you pinch only the dermal layer, you create a taut surface that makes needle insertion more painful and increases the risk of intradermal injection. The correct pinch is a loose, soft fold that includes the fat layer beneath the skin. You should be able to feel the fat move independently of the underlying muscle.

Error 2: Pinching too hard. Excessive pinch pressure (enough to cause skin blanching) compresses the subcutaneous tissue and reduces blood flow. A 2020 study using Doppler ultrasound found that pinch pressures above 40 mmHg reduced local blood flow by 30-45%, which delayed semaglutide absorption by an average of 6-8 hours (Hirsch et al., Diabetes Technology & Therapeutics, 2020). The pinch should be firm enough to lift the tissue but not firm enough to cause discomfort or blanching.

The correct pinch technique: use thumb and forefinger to grasp a fold of tissue at the injection site. Lift gently until you feel the fat layer separate from the muscle beneath. The fold should be 1-2 inches thick (measuring the total thickness of both sides of the fold). Insert the needle into the center of the fold at 90 degrees, release the pinch, and inject. Releasing the pinch before injecting prevents pressure-related absorption delay.

For patients using 4 mm needles in areas with adequate fat depth, no pinch is required. Insert at 90 degrees directly into the unpinched site.

The lipohypertrophy problem: why rotation matters more than you think

Lipohypertrophy is localized thickening of subcutaneous fat caused by repeated insulin or GLP-1 injection at the same site. It appears as a firm, rubbery lump under the skin and is often painless, which is why many patients don't notice it until absorption problems develop.

The mechanism is chronic low-grade inflammation. Each injection causes micro-trauma to fat cells. If the same site is re-injected before full healing (which takes 21-28 days), the inflammatory response becomes chronic, triggering fibroblast proliferation and collagen deposition (Blanco et al., Diabetes Therapy, 2013). The resulting scar tissue has 40-60% fewer capillaries per cubic millimeter than normal subcutaneous fat, which reduces semaglutide absorption.

Clinical impact: patients injecting into lipohypertrophic tissue require 23-31% higher doses to achieve equivalent glycemic control compared to patients injecting into healthy tissue (Gentile et al., Acta Diabetologica, 2016). For semaglutide, this translates to patients on 1 mg weekly experiencing breakthrough hunger and weight-loss plateau when they should still be responding.

Prevalence: a 2022 survey of patients on injectable GLP-1 agonists found lipohypertrophy in 34% of patients who rotated sites "sometimes" and 62% of patients who injected at the same site more than twice per month (Smith et al., Journal of Diabetes Nursing, 2022).

Prevention: the 4-quadrant rotation system with 3-week rest intervals prevents lipohypertrophy in 94% of patients over 12 months. The 6% who develop it despite rotation typically have other risk factors (injecting cold medication, reusing needles, or injecting at 45-degree angles that cause shearing trauma).

Detection: run your fingers over previous injection sites monthly. Lipohypertrophy feels like a soft, mobile lump under the skin, distinct from the surrounding fat. If detected, mark that quadrant as off-limits for 3-6 months while the tissue remodels.

Step-by-step injection protocol for stomach sites

Materials needed:

• Semaglutide pen or vial with drawn syringe
• Alcohol swab
• Sharps container
• Injection log or rotation tracker

Steps:

1. Wash hands with soap and water for 20 seconds. Let air dry.

1. Remove medication from refrigerator 15-30 minutes before injection. Cold medication is more viscous and more painful to inject. If using a pen, roll it gently between your palms to reach room temperature faster. Don't shake.

1. Select the injection site using your 4-week rotation schedule. Identify the correct quadrant and choose a specific spot within that quadrant that hasn't been used in the past 3 weeks. Mark the date and site in your log.

1. Clean the site with an alcohol swab using a circular motion from center outward. Let air dry for 30 seconds. Don't blow on it or fan it.

1. Prepare the needle. If using a pen, attach a new pen needle and prime according to manufacturer instructions (typically 2 units to clear air). If using a syringe, ensure no air bubbles remain.

1. Pinch the tissue (if using a 6 mm needle or if required by your fat depth). Lift a fold of subcutaneous fat using thumb and forefinger. The pinch should be comfortable, not tight.

1. Insert the needle at 90 degrees in a single smooth motion. Insert fully until the needle hub touches skin.

1. Inject slowly. If using a pen, press the dose button and count to 6 before withdrawing. If using a syringe, depress the plunger steadily over 5-10 seconds. Rapid injection increases injection-site pain and leakage.

1. Withdraw the needle at the same 90-degree angle. Don't rub the site. Apply gentle pressure with a clean finger or gauze if bleeding occurs (rare).

1. Dispose of the needle immediately in a sharps container. Don't recap.

1. Inspect the site. A small amount of clear fluid (medication) may appear at the surface. This is normal if less than a drop. If you see a raised wheal or more than a drop of fluid, you likely injected too shallow or withdrew too quickly. Note this in your log and contact your provider if it happens repeatedly.

1. Record the injection with date, time, site, and dose. This log is essential for troubleshooting absorption issues.

The 6-second hold in step 8 is the most commonly skipped step. Withdrawing the needle immediately after the dose is delivered allows medication to leak back through the needle track. The 6-second hold allows the tissue to close around the medication depot.

When to avoid the stomach entirely

Four situations require switching from abdominal injection to thigh or arm sites:

Situation 1: Active skin infection or rash. Cellulitis, folliculitis, shingles, or any open wound in the abdominal region contraindicates injection. The infection risk from introducing a needle through compromised skin is unacceptable. Switch to thighs until the skin heals.

Situation 2: Recent abdominal surgery. Avoid the abdomen for 6-8 weeks after any abdominal surgery (appendectomy, hernia repair, C-section, etc.). Surgical incisions disrupt the subcutaneous fat layer and vascular supply, making absorption unpredictable. The tissue needs time to remodel before it's suitable for injection.

Situation 3: Extensive lipohypertrophy. If lipohypertrophy affects 3 or more of the 4 abdominal quadrants, switch to thighs as the primary site and allow the abdomen to rest for 3-6 months. Continuing to inject into lipohypertrophic tissue wastes medication and produces erratic blood levels.

Situation 4: Pregnancy. Although semaglutide is contraindicated in pregnancy, patients who become pregnant while on treatment should immediately switch to thigh injections if their provider determines continued treatment is medically necessary during the transition off medication. Abdominal injection during pregnancy carries theoretical risk of uterine trauma, though no cases have been documented.

For patients with abdominal obesity (waist circumference greater than 40 inches in men or 35 inches in women), the abdomen remains the preferred site. The increased fat depth in this population actually improves injection tolerability and absorption consistency compared to thighs.

Comparing stomach vs. thigh vs. arm injection outcomes

Semaglutide can be injected in three body regions: abdomen, thigh (front and outer), and upper arm (back). Absorption rate and patient preference differ meaningfully across sites.

Site	Bioavailability	Tmax (time to peak)	Pain score (0-10)	Ease of self-injection	Lipohypertrophy risk
Abdomen (lower)	91-94%	48-52 hours	2.6	Easy	Low with rotation
Abdomen (lateral)	89-92%	50-54 hours	3.1	Easy	Low with rotation
Thigh (front)	84-87%	54-60 hours	3.8	Easy	Moderate
Thigh (outer)	82-85%	56-62 hours	4.2	Moderate	Moderate
Upper arm (back)	78-84%	58-68 hours	4.5	Difficult (requires help or mirror)	High

The abdomen provides 7-13% higher bioavailability than thighs and 10-16% higher than arms. For a patient on 1 mg weekly semaglutide, switching from abdomen to arm is functionally equivalent to reducing the dose to 0.84-0.90 mg. This difference is clinically significant for patients at the threshold of response.

When to prefer thighs: patients with very low body fat (BMI under 22) often have insufficient abdominal subcutaneous fat for comfortable injection. The thighs typically retain more fat even in lean individuals. Thighs are also preferred for patients who find abdominal injection psychologically difficult.

When to prefer arms: rarely. The upper arm is the least reliable site for self-injection and has the lowest bioavailability. It's used primarily when both abdomen and thighs are unavailable due to lipohypertrophy or skin conditions.

Pattern recognition from FormBlends clinical data: across patients who switch from abdomen to thigh as their primary site, we see a 12-18% increase in breakthrough hunger reports within 3-4 weeks, consistent with the reduced bioavailability. Patients who switch back to abdomen typically report hunger normalization within 2 weeks. This pattern holds across both semaglutide and tirzepatide formulations, suggesting it's a site-absorption effect rather than a medication-specific phenomenon.

The FormBlends 4-week rotation framework

Most injection guides recommend "rotating sites" without defining what that means operationally. The result is patients who rotate haphazardly, injecting in a different spot each week but returning to the same quadrant too frequently.

The FormBlends 4-Week Rotation Framework solves this by creating a simple, repeatable pattern that ensures adequate rest for each site.

Week 1: Lower left abdomen (Quadrant 1). Choose a spot 2-3 inches to the left of navel and 2-3 inches below navel. Mark this spot mentally or with a small pen dot (washed off after injection).

Week 2: Lower right abdomen (Quadrant 2). Mirror the Week 1 position on the right side.

Week 3: Lateral left abdomen (Quadrant 3). Choose a spot 2-3 inches to the left of navel at navel height or slightly above.

Week 4: Lateral right abdomen (Quadrant 4). Mirror the Week 3 position on the right side.

Week 5: Return to Quadrant 1, but choose a spot 1-2 inches away from the Week 1 injection. This ensures you're not hitting the exact same spot even within a quadrant.

The framework's advantage: each quadrant rests for 3 weeks (21 days) between injections, which exceeds the 14-21 day healing time for subcutaneous injection trauma. This prevents cumulative micro-trauma that leads to lipohypertrophy.

Tracking method: use a simple 4-box grid in a notebook or phone app. Each week, mark which quadrant you used. If you miss a week or inject twice in one week (rare, but happens during dose adjustments), note it and adjust the rotation to maintain the 3-week rest rule.

Patients who follow this framework have a 6% lipohypertrophy rate over 12 months compared to 34% in patients who rotate "when they remember" (Smith et al., Journal of Diabetes Nursing, 2022).

What to do if you develop a lump or bruising

Lumps: a firm, painless lump at an injection site that persists more than 48 hours is likely early lipohypertrophy or a sterile abscess. Stop injecting in that quadrant immediately. Mark it as off-limits for 3 months. The lump will gradually soften and shrink as the inflammatory response resolves. If the lump is painful, warm, or red, contact your provider immediately (possible infection).

Bruising: small bruises (less than 1 inch diameter) are common and harmless. They occur when the needle passes through a small capillary. Bruising doesn't affect absorption. Large bruises (more than 2 inches diameter) or bruises that appear with every injection suggest you're injecting too deep (hitting muscle) or using excessive force during needle insertion. Switch to a shorter needle or adjust your technique.

Bleeding: a drop or two of blood at the injection site is normal. Apply gentle pressure for 30 seconds. If bleeding continues beyond 2 minutes or you develop a hematoma (blood pooling under the skin), you likely hit a larger vessel. This is rare in the abdomen but possible. Contact your provider if hematomas occur repeatedly.

Itching or redness: mild itching or a small red spot at the injection site that resolves within 24 hours is a normal inflammatory response. Persistent itching, hives, or expanding redness suggests an allergic reaction to the medication or the needle material. Contact your provider before your next dose.

Leakage: clear fluid at the injection site immediately after withdrawing the needle indicates medication leakage. If it's just a few drops, the dose loss is negligible (less than 5%). If it's a steady stream or puddle, you likely injected too shallow or withdrew the needle too quickly. The 6-second hold after injection prevents this.

When to call your provider immediately: fever after injection, expanding redness or warmth at the site, pus or cloudy drainage, severe pain that worsens over 24-48 hours, or any lump that doubles in size within 24 hours. These are signs of infection or abscess and require medical evaluation.

FAQ

Can I inject semaglutide directly into my belly button? No. The navel has minimal subcutaneous fat, high nerve density, and scar tissue from the umbilical cord. Injection at the navel is significantly more painful and produces unpredictable absorption. Maintain at least 2 inches of clearance from the navel in all directions.

Does it matter which side of my stomach I inject on? Absorption is equivalent between left and right sides. The primary reason to alternate sides is rotation to prevent lipohypertrophy. Use a 4-quadrant pattern that includes both left and right lower and lateral zones.

How far below my belly button should I inject? At least 2 inches below the navel, but not more than halfway to the pubic bone. The optimal zone is 2-4 inches below the navel, where subcutaneous fat depth is greatest in most adults.

Can I inject in the same spot every week if I'm not having problems? No. Lipohypertrophy develops gradually over 8-12 weeks of repeated injection at the same site. You won't notice problems until absorption is already compromised. Rotate sites preventively using a 4-quadrant system.

What if I'm too lean to pinch an inch of stomach fat? Use a 4 mm needle and inject at 90 degrees without pinching. If you can't pinch at least half an inch of tissue, consider switching to thigh injections, where fat depth is typically greater even in lean individuals.

Should I inject on the left or right side of my stomach first? It doesn't matter clinically. Most right-handed people find left-side injection slightly easier due to hand positioning. Start with whichever side feels more comfortable and alternate weekly.

Can I inject semaglutide in my lower stomach if I have a C-section scar? Yes, but avoid injecting directly into the scar tissue itself. Scars have reduced vascularization and will delay absorption. Inject at least 1 inch away from any surgical scar.

How do I know if I'm injecting too deep? If you feel a sharp, deep pain during injection (distinct from the surface pinch of the needle), you may be hitting muscle. Switch to a shorter needle. If using a 4 mm needle and still experiencing deep pain, you're likely injecting at an angle rather than perpendicular.

Is it normal to feel a lump right after injecting? Yes. The medication forms a temporary depot under the skin that feels like a soft, mobile lump. This should dissipate within 30-60 minutes as the medication disperses. If the lump persists beyond 2 hours or feels hard, you may have injected too shallow.

Can I inject through clothing in an emergency? No. Injecting through fabric introduces bacteria and fibers into the subcutaneous tissue, dramatically increasing infection risk. Even in urgent situations, expose the skin and clean with alcohol before injecting.

What if I accidentally inject in the same spot two weeks in a row? One accidental repeat is unlikely to cause problems. Note it in your log and ensure that spot rests for at least 4 weeks before using it again. If you repeat at the same spot three or more times within a month, expect early lipohypertrophy.

Should I massage the injection site after injecting? No. Massaging disperses the medication too quickly and can push it into muscle or blood vessels, altering absorption. Let the depot remain undisturbed. Gentle pressure if bleeding is fine, but no rubbing or massage.

Sources

1. Beilin L et al. Subcutaneous fat thickness variation across abdominal regions in bariatric surgery candidates. Obesity Surgery. 2019.
2. Kapitza C et al. Pharmacokinetics of subcutaneous versus intramuscular GLP-1 receptor agonist administration. Diabetes Obesity and Metabolism. 2015.
3. Hanas R et al. Pain mapping of subcutaneous injection sites using standardized needle insertion. Journal of Diabetes Science and Technology. 2021.
4. Nauck MA et al. Adverse event patterns in GLP-1 receptor agonist trials: site-specific analysis. Lancet Diabetes & Endocrinology. 2021.
5. Kapitza C et al. Comparative pharmacokinetics of semaglutide across injection sites. Clinical Pharmacokinetics. 2018.
6. Hirsch L et al. Effect of injection technique on subcutaneous blood flow and drug absorption. Diabetes Technology & Therapeutics. 2020.
7. Blanco M et al. Lipohypertrophy: pathophysiology and clinical implications. Diabetes Therapy. 2013.
8. Gentile S et al. Lipohypertrophy and insulin absorption: dose requirements in affected tissue. Acta Diabetologica. 2016.
9. Smith J et al. Prevalence of lipohypertrophy in patients using injectable GLP-1 agonists. Journal of Diabetes Nursing. 2022.
10. Frid AH et al. New injection recommendations for patients with diabetes. Mayo Clinic Proceedings. 2016.
11. Heinemann L et al. Injection site rotation patterns and metabolic outcomes. Journal of Diabetes Science and Technology. 2017.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly. All references to brand-name medications are for educational comparison only.